As markets trade near record highs, the article highlights three dividend-oriented stock ideas for November: Novo Nordisk, Moody's and Mastercard. Novo Nordisk has fallen roughly 70% from its peak amid competition from Eli Lilly and compounding pharmacies, yet trades under 14x 2025 earnings with a near-3.6% yield and exposure to a potentially $150bn obesity market following a CEO-led strategic shift. Moody's is presented as a defensive, high-margin data and ratings franchise with 15 consecutive years of dividend increases, a payout ratio around 25% of 2025 EPS, a ~32x 2025 P/E and expected mid-teens-ish revenue/earnings growth of 11–12%; Mastercard is framed as a cash-flow generative payments toll with 14 years of raises, >32x 2025 earnings and analyst-expected ~15% annual EPS growth, benefiting from secular card adoption and inflation-linked transaction fees.
Novo Nordisk has plunged nearly 70% from its all-time high as competition from Eli Lilly and persistent compounding-pharmacy pressure eroded market share. Shares trade at under 14 times 2025 earnings estimates and yield about 3.6%, implying valuation has priced in substantial downside. Management’s recent CEO change and a more aggressive M&A and sales posture, combined with exposure to a potentially $150 billion obesity market, create credible upside if competitive trends stabilize. Moody's is framed as a defensive, high-margin data and ratings franchise with a century-long reputation and steady demand given ongoing corporate and sovereign borrowing. The company has raised its dividend for 15 consecutive years, carries a payout roughly one quarter of 2025 earnings, and trades at about 32x 2025 estimates versus analyst growth of 11–12% annually over the next 3–5 years. That mix supports dividend durability and moderate capital appreciation, though the valuation reflects expected growth rather than deep value. Mastercard is described as a cash-flow machine that functions like a toll on transactions, with percentage-based fees that should rise with inflation and support an analyst-expected ~15% annual EPS growth. The firm has increased its dividend for 14 consecutive years and trades just above 32x 2025 earnings, a premium consistent with high-quality secular growth. Together these names highlight dividend income opportunities outside tech while presenting distinct risks: idiosyncratic competition at Novo Nordisk, credit-cycle exposure for Moody's, and consumer-spending cyclicality for Mastercard.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
